Molecular mechanisms of crystal-related kidney inflammation and injury. Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease

Nephrology Dialysis Transplantation

Volumn 29, Issue 3, 2014, Pages 507-514

  Mulay, Shrikant R ^a   Evan, Andrew ^b   Anders, Hans Joachim ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cystinosis; Gout; Myeloma cast nephropathy; Nephrolithiasis; Rhabdomyolysis

Indexed keywords

CRYOPYRIN; CRYSTALLIN; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 18; INTERLEUKIN 18 RECEPTOR; INTERLEUKIN 1BETA; INFLAMMASOME; URIC ACID;

ADENINE NEPHROPATHY; ARTICLE; CHOLESTEROL EMBOLISM; CHRONIC KIDNEY DISEASE; CONTRAST INDUCED NEPHROPATHY; CRYSTAL; CRYSTALLIZATION; CYSTINOSIS; DISEASE COURSE; DRUG INDUCED KIDNEY INJURY; ENZYME ACTIVATION; ENZYME RELEASE; HUMAN; KIDNEY CALCIFICATION; KIDNEY DISEASE; KIDNEY INJURY; LEUKOCYTE FUNCTION; LIGHT CHAIN FANCONI SYNDROME; MOLECULAR MECHANICS; MYELOMA CAST NEPHROPATHY; NEPHRITIS; NEPHROLITHIASIS; NONHUMAN; OXALIC ACID NEPHROPATHY; PATHOGENESIS; PELVIC STRUVIT STONE; PHOSPHATE NEPHROPATHY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RHABDOMYOLYSIS; SIGNAL TRANSDUCTION; STONE FORMATION; TISSUE REGENERATION; URIC ACID NEPHROPATHY; ANIMAL; GOUT; IMMUNOLOGY; KIDNEY; METABOLISM; PATHOLOGY; PHYSIOLOGY; VASCULARIZATION;

ANIMALS; EMBOLISM, CHOLESTEROL; GOUT; HUMANS; INFLAMMASOMES; KIDNEY; KIDNEY CALCULI; NEPHRITIS; URIC ACID;

EID: 84895762644     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft248     Document Type: Article

References (48)

1. Evan AP, Weinman EJ, Wu XR et al. Comparison of the pathology of interstitial plaque in human ICSF stone patients to NHERF-1 and THP-null mice. Urol Res 2010; 38: 439-452
2. Worcester EM, Coe FL. Clinical practice. Calcium kidney stones. N Engl J Med 2010; 363: 954-963
3. Saric M, Kronzon I. Cholesterol embolization syndrome. Curr Opin Cardiol 2011; 26: 472-479
4. Ehara T, Yazawa M, Konishi K et al. Renal cholesterol embolism: analysis of two spontaneous autopsy cases. Nephrology (Carlton) 2005; 10: 90-96
5. Coe FL, Evan A, Worcester E. Kidney stone disease. J Clin Invest 2005; 115: 2598-2608
6. Yarlagadda SG, Perazella MA. Drug-induced crystal nephropathy: an update. Expert Opin Drug Saf 2008; 7: 147-158
7. Sanders PW. Mechanisms of light chain injury along the tubular nephron. J Am Soc Nephrol 2012; 23: 1777-1781
8. Khan SR. Nephrocalcinosis in animal models with and without stones. Urol Res 2010; 38: 429-438
9. Messiaen T, Deret S, Mougenot B et al. Adult Fanconi syndrome secondary to light chain gammopathy. Clinicopathologic heterogeneity and unusual features in 11 patients. Medicine (Baltimore) 2000; 79: 135-154
10. Nickeleit V, Mihatsch MJ. Uric acid nephropathy and end-stage renal disease - review of a non-disease. Nephrol Dial Transplant 1997; 12: 1832-1838
11. Barlow KA, Beilin LJ. Renal disease in primary gout. Q J Med 1968; 37: 79-96
12. Evan AP, Lingeman JE, Coe FL et al. Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest 2003; 111: 607-616
13. Rule AD, Krambeck AE, Lieske JC. Chronic kidney disease in kidney stone formers. Clin J Am Soc Nephrol 2011; 6: 2069-2075
14. Saucier NA, Sinha MK, Liang KV et al. Risk factors for CKD in persons with kidney stones: a case-control study in Olmsted County, Minnesota. Am J Kidney Dis 2010; 55: 61-68
15. Martinon F, Petrilli V, Mayor A et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-241
16. Duewell P, Kono H, Rayner KJ et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464: 1357-1361
17. Jin C, Frayssinet P, Pelker R et al. NLRP3 inflammasome plays a critical role in the pathogenesis of hydroxyapatite-associated arthropathy. Proc Natl Acad Sci USA 2011; 108: 14867-14872
18. Mulay SR, Kulkarni OP, Rupanagudi KV et al. Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1beta secretion. J Clin Invest 2013; 123: 236-246
19. Halle A, Hornung V, Petzold GC et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 2008; 9: 857-865
20. Hornung V, Bauernfeind F, Halle A et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008; 9: 847-856
21. Dostert C, Guarda G, Romero JF et al. Malarial hemozoin is a Nalp3 inflammasome activating danger signal. PLoS One 2009; 4: e6510
22. Darisipudi MN, Thomasova D, Mulay SR et al. Uromodulin triggers IL- 1beta-dependent innate immunity via the NLRP3 inflammasome. J Am Soc Nephrol 2012; 23: 1783-1789
23. Anders HJ, Muruve DA. The inflammasomes in kidney disease. J Am Soc Nephrol 2011; 22: 1007-1018
24. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140: 805-820
25. Mankan AK, Kubarenko A, Hornung V. Immunology in clinic review series; focus on autoinflammatory diseases: inflammasomes: mechanisms of activation. Clin Exp Immunol 2012; 167: 369-381
26. Dinarello CA. Interleukin-1 beta and the autoinflammatory diseases. N Engl J Med 2009; 360: 2467-2470
27. Khan SR. Crystal-induced inflammation of the kidneys: results from human studies, animal models, and tissue-culture studies. Clin Exp Nephrol 2004; 8: 75-88
28. Thongboonkerd V, Semangoen T, Sinchaikul S et al. Proteomic analysis of calcium oxalate monohydrate crystal-induced cytotoxicity in distal renal tubular cells. J Proteome Res 2008; 7: 4689-4700
29. Chaiyarit S, Thongboonkerd V. Changes in mitochondrial proteome of renal tubular cells induced by calcium oxalate monohydrate crystal adhesion and internalization are related to mitochondrial dysfunction. J Proteome Res 2012 April 27 [Epub ahead of print]
30. Anders HJ, Vielhauer V, Schlondorff D. Chemokines and chemokine receptors are involved in the resolution or progression of renal disease. Kidney Int 2003; 63: 401-415
31. Swaminathan S, Griffin MD. First responders: understanding monocytelineage traffic in the acutely injured kidney. Kidney Int 2008; 74: 1509-1511
32. Anders HJ. Four danger response programs determine glomerular and tubulointerstitial kidney pathology: clotting, inflammation, epithelial and mesenchymal healing. Organogenesis 2012; 8: 29-40
33. Khan SR. Reactive oxygen species as the molecular modulators of calcium oxalate kidney stone formation: evidence from clinical and experimental investigations. J Urol 2013; 189: 803-811
34. Eltzschig HK, Eckle T. Ischemia and reperfusion - from mechanism to translation. Nat Med 2011; 17: 1391-1401
35. Mantovani A, Sica A, Sozzani S et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677-686
36. Robinson RR, Yarger WE. Acute uric acid nephropathy. Arch Intern Med 1977; 137: 839-840
37. Vervaet BA, Verhulst A, Dauwe SE et al. An active renal crystal clearance mechanism in rat and man. Kidney Int 2009; 75: 41-51
38. Okada A, Yasui T, Fujii Y et al. Renal macrophage migration and crystal phagocytosis via inflammatory-related gene expression during kidney stone formation and elimination in mice: detection by association analysis of stone-related gene expression and microstructural observation. J Bone Miner Res 2010; 25: 2701-2711
39. Okada A, Yasui T, Hamamoto S et al. Genome-wide analysis of genes related to kidney stone formation and elimination in the calcium oxalate nephrolithiasis model mouse: detection of stone-preventive factors and involvement of macrophage activity. J Bone Miner Res 2009; 24: 908-924
40. De Water R, Noordermeer C, Houtsmuller AB et al. Role of macrophages in nephrolithiasis in rats: an analysis of the renal interstitium. Am J Kidney Dis 2000; 36: 615-625
41. Knauf F, Asplin J, Granja I et al. NALP3-mediated inflammation is the principal cause of progressive renal failure in oxalate nephropathy. Kidney Int 2013; 83: in press
42. Anders HJ, Ryu M. Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int 2011; 80: 915-925
43. Zhang MZ, Yao B, Yang S et al. CSF-1 signaling mediates recovery from acute kidney injury. J Clin Invest 2012; 122: 4519-4532
44. Banchereau J, Pascual V, O'garra A. From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol 2012; 13: 925-931
45. Buckley CD, Gilroy DW, Serhan CN et al. The resolution of inflammation. Nat Rev Immunol 2013; 13: 59-66
46. Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 2011; 121: 4210-4221
47. Evan AP, Lingeman JE, Coe FL et al. Crystal-associated nephropathy in patients with brushite nephrolithiasis. Kidney Int 2005; 67: 576-591
48. Herlitz LC, D'agati VD, Markowitz GS. Crystalline nephropathies. Arch Pathol Lab Med 2012; 136: 713-720